Brief: Aker Biomarine Q1 Adjusted EBITDA $12.5 Mln
April 30 (Reuters) - Aker Biomarine ASA AKBM.OL: AKER BIOMARINE Q1 ADJUSTED EBITDA USD 12.5 MILLION AKER BIOMARINE Q1 REVENUE USD 57.3 MILLION FOLLOWING RECENT INTEREST IN HUMAN HEALTH INGREDIENT BUSINESS UNIT, CO IS EXPLORING ALTERNATIVES, WORKING TOWARDS TRANSACTION IN 2026 Source text: ID:nObi1byVka Further company coverage: AKBM.OL (Gdansk Newsroom) ((gdansk.newsroom@thomsonreuters.com;))
Recent news on Aker Biomarine ASA
See all newsBrief: Aker Biomarine Secures Lysoveta Contract
Norway's Aker BioMarine Q1 revenue rises 13% on record krill oil sales
Brief: Aker Biomarine Q1 Adjusted EBITDA $12.5 Mln
Norway's Aker BioMarine exploring alternatives for Human Health Ingredient unit
Brief: Aker BioMarine Q4 Adjusted EBITDA USD 10.6 Million